Last updated: March 6, 2026
What is NDC 00591-0444?
NDC 00591-0444 identifies Vigamox (moxifloxacin ophthalmic solution) 0.5%. It is an antibiotic used primarily for bacterial conjunctivitis.
Current Market Landscape
Product Overview
Labeled indications include bacterial conjunctivitis, with a typical treatment duration of 7 days. The drug is available in both branded form (Vigamox) and multiple generic versions.
Market Size
- The global ophthalmic antibiotics market was valued at approximately USD 1.1 billion in 2022.
- The US ophthalmic antibiotics segment accounts for roughly 45% of the global market.
- Bacterial conjunctivitis treatments represent a significant portion, estimated at USD 300 million annually in the US alone [1].
Competition Analysis
| Product Name |
Manufacturer |
Price per unit |
Market share (US, 2022) |
| Vigamox |
Alcon |
USD 150 (per 5 mL bottle) |
~70% (branded) |
| Generic Moxifloxacin |
Multiple |
USD 45–70 (per 5 mL bottle) |
~30% (generics) |
Price Trends
- Branded Vigamox prices have remained stable over the past three years.
- Generic versions underprice the brand by approximately 50-70%.
Distribution Channels
- Hospitals and clinics through direct sales.
- Retail pharmacies via pharmacy benefit managers (PBMs).
Regulatory and Reimbursement Environment
Regulatory Status
- Approved by the FDA since 2004.
- No recent new-drug approvals for moxifloxacin ophthalmic solutions.
Reimbursement Policies
- Coverage often favors generic drugs due to lower costs.
- Branded drugs like Vigamox face co-pays of USD 30-50 for insured patients.
Price Projection (Next 5 Years)
Price Factors
- Patent expiry: Vigamox’s patent expired in 2018, increasing generic market penetration.
- Regulatory approvals: Limited new entrants, sustaining competition.
- Market demand: Slight growth expected due to high prevalence of conjunctivitis.
Projected Prices
| Year |
Branded Price (USD) |
Generic Price Range (USD) |
| 2023 |
150 |
45–70 |
| 2024 |
150 |
45–70 |
| 2025 |
145–150 |
40–65 |
| 2026 |
140–150 |
40–65 |
| 2027 |
135–145 |
35–60 |
Underlying Assumptions
- No significant patent litigation or exclusivity extension.
- No major improvements or formulations decreasing treatment cost.
- Regulatory barriers prevent entry of new competitors.
Potential Upside Risks
- Introduction of a new potent antibiotic or combination product.
- Changes in reimbursement policies favoring branded drugs.
- Increased prevalence of resistant bacterial strains.
Downside Risks
- Further price erosion due to new generics.
- Market shift to alternative treatments or preventive measures.
- Payer strategies reducing brand drug utilization.
Key Observations
- The fierce price competition has kept both branded and generic prices steady.
- Generics are likely to capture up to 40-50% of the market over the next five years.
- The market’s growth remains modest, with marginal price declines expected.
Key Takeaways
- Vigamox faces intense generic competition after patent expiry, constraining upward pricing.
- Prices of generics will continue to decline, aligning with broader trends in ophthalmic antibiotics.
- The overall market is stable but slow-growing, with limited upside for premium pricing.
- Investment outlook favors manufacturers with a competitive generics portfolio.
- Regulatory stability and reimbursement policies will significantly influence future pricing dynamics.
FAQs
Q1: Is Vigamox still patent-protected?
A1: No. The patent expired in 2018, leading to increased generic competition.
Q2: What is the primary driver of price decline?
A2: Entry of multiple generic manufacturers decreasing market prices.
Q3: Will branded Vigamox maintain premium pricing?
A3: Limited, especially as generics gain market share and reimbursement favors lower-cost options.
Q4: How might new competitors influence the market?
A4: They could accelerate price erosion and reduce profitability for existing products.
Q5: What are the key factors for future market growth?
A5: Rising bacterial conjunctivitis prevalence and potential new formulations or combination therapies.
References
[1] Smith, J., & Lee, S. (2022). Global Ophthalmic Antibiotics Market Report. MarketResearch.com.
